Last mentioned: Mar 24, 2026
Expected Data Readouts
Anticipated primary endpoint results for the ALTO-100 Phase 2b/3 study in MDD.
$120M Private Placement
CFO Nick Smith announces a major financing round to accelerate late-stage clinical programs.
CFO Briefing
CFO Nick Smith discusses the strategic implications of the $120M financing for the firm's pipeline.
Earnings & Funding
Alto reports Q4 earnings beating EPS estimates and announces the $120M private placement.
1-Year High
ANRO stock hits a new 52-week high amid positive sentiment in the psychiatric therapy market.
Phase 2b Expansion
Company expands clinical trials for ALTO-100 targeting specific biotypes of depression.
Initial Public Offering
Alto Neuroscience goes public on the NYSE to fund its precision psychiatry platform.
Alto Neuroscience has successfully raised $120 million through a private placement, a significant capital injection aimed at accelerating its precision psychiatry platform. Led by CFO Nick Smith, the financing highlights growing investor confidence in biomarker-driven approaches to treating central nervous system (CNS) disorders.
Alto Neuroscience has completed a $120 million private placement financing to accelerate its biomarker-driven clinical programs. Led by CFO Nick Smith, the capital injection extends the company's cash runway through critical Phase 2b readouts in depression and schizophrenia.
Alto Neuroscience has successfully raised $120 million through a private placement financing to accelerate its clinical-stage pipeline of precision medicines for mental health. Led by CFO Nick Smith, the funding underscores investor confidence in the company's AI-driven approach to identifying biomarkers for psychiatric disorders.